South Rampart Pharma
southeastLife SciencesFounded 2016
South Rampart Pharma’s proprietary compounds effectively reduce pain and fever in preclinical studies without liver and kidney toxicity associated with current treatment. The company’s non-opioid compounds, licensed from LSU Health New Orleans, also greatly reduce the potential for abuse. The company won a $1.9 million National Institutes of Health Phase I/II award in 2022 to support the clinical development of its lead, non-opioid candidate, SRP-3D (DA).
Contact Info
478 Broadway Street, New Orleans, LA 70118